"Immunotherapy, Adoptive" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
| Descriptor ID |
D016219
|
| MeSH Number(s) |
E02.095.465.425.400.330.050.400 E05.478.550.520.050.400
|
| Concept/Terms |
Immunotherapy, Adoptive- Immunotherapy, Adoptive
- Immunotherapy, Adoptive Cellular
- Adoptive Immunotherapy
- Adoptive Immunotherapies
- Immunotherapies, Adoptive
- Cellular Immunotherapy, Adoptive
- Adoptive Cellular Immunotherapies
- Cellular Immunotherapies, Adoptive
- Immunotherapies, Adoptive Cellular
- Adoptive Cellular Immunotherapy
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy, Adoptive".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy, Adoptive".
This graph shows the total number of publications written about "Immunotherapy, Adoptive" by people in this website by year, and whether "Immunotherapy, Adoptive" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 1 | 4 |
| 1996 | 2 | 1 | 3 |
| 1997 | 1 | 0 | 1 |
| 1998 | 8 | 2 | 10 |
| 2000 | 1 | 1 | 2 |
| 2001 | 5 | 1 | 6 |
| 2002 | 3 | 5 | 8 |
| 2003 | 3 | 3 | 6 |
| 2004 | 6 | 0 | 6 |
| 2005 | 4 | 0 | 4 |
| 2006 | 8 | 2 | 10 |
| 2007 | 6 | 1 | 7 |
| 2008 | 4 | 0 | 4 |
| 2009 | 3 | 1 | 4 |
| 2010 | 7 | 2 | 9 |
| 2011 | 11 | 0 | 11 |
| 2012 | 6 | 4 | 10 |
| 2013 | 5 | 4 | 9 |
| 2014 | 9 | 4 | 13 |
| 2015 | 7 | 0 | 7 |
| 2016 | 2 | 7 | 9 |
| 2017 | 13 | 2 | 15 |
| 2018 | 12 | 3 | 15 |
| 2019 | 13 | 7 | 20 |
| 2020 | 18 | 7 | 25 |
| 2021 | 9 | 5 | 14 |
| 2022 | 5 | 20 | 25 |
| 2023 | 6 | 23 | 29 |
| 2024 | 30 | 10 | 40 |
| 2025 | 26 | 4 | 30 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy, Adoptive" by people in Profiles.
-
Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel. Blood Adv. 2025 Oct 14; 9(19):5070-5084.
-
TIGIT Affects CAR NK-cell Effector Function in the Solid Tumor Microenvironment by Modulating Immune Synapse Strength. Cancer Immunol Res. 2025 Oct 01; 13(10):1576-1590.
-
Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas. Cancer Immunol Res. 2025 Oct 01; 13(10):1591-1608.
-
Next-generation multiplex-edited CAR-NK cells: more edits, more power? J Immunother Cancer. 2025 Sep 15; 13(9).
-
Central memory-enriched V?9Vd2 ?d T cells via TGF-? expansion demonstrate enhanced in vivo efficacy against metastatic osteosarcoma. Front Immunol. 2025; 16:1657760.
-
B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response. Clin Cancer Res. 2025 Sep 02; 31(17):3754-3770.
-
Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement. Blood Adv. 2025 Aug 26; 9(16):4081-4089.
-
Opportunities to Improve Antibiotic Stewardship, and Identification of Blood Biomarkers Associated with Bacteremia Following CAR-T Cell Therapy. Transplant Cell Ther. 2025 Oct; 31(10):838.e1-838.e16.
-
IL-7 armed binary CAR T cell strategy to augment potency against solid tumors. Front Immunol. 2025; 16:1618404.
-
Constitutive IL-7 signaling promotes CAR-NK cell survival in the solid tumor microenvironment but impairs tumor control. J Immunother Cancer. 2025 Jul 23; 13(7).